Trump Administration Mulls COVID-19 Vaccine Ban: Report
PorAinvest
lunes, 25 de agosto de 2025, 6:17 pm ET1 min de lectura
BNTX--
Dr. Malhotra, a British cardiologist and vocal vaccine critic, told The Daily Beast that members of President Donald Trump's family support Kennedy's position, despite lacking medical or scientific expertise. Malhotra is an adviser to Make America Healthy Again (MAHA) Action, a group aligned with Kennedy's public health agenda [1].
The potential withdrawal of COVID-19 vaccines could have significant implications for the market. Following the report, stocks of vaccine manufacturers, including Pfizer Inc. (NYSE:PFE), BioNTech SE (NASDAQ:BNTX), Moderna Inc. (NASDAQ:MRNA), and Novavax Inc. (NASDAQ:NVAX), began trading lower. Pfizer's stock fell by 2.53%, BioNTech's by 3.31%, Moderna's by 4.48%, and Novavax's by 4.27% [2].
The decision to withdraw the vaccine is reportedly rooted in skepticism about the safety of mRNA vaccines. Central to Kennedy's stance is a 2022 peer-reviewed paper published in the journal Vaccine, which claimed mRNA vaccines were associated with a 16% higher rate of serious adverse events than placebos in clinical trials. However, the study has been widely dismissed by the scientific community due to methodological concerns and claims of bias [1].
The White House has denied these claims. White House spokesperson Kush Desai stated, "The Administration is relying on Gold Standard Science and is committed to radical transparency to make decisions that affect all Americans. Any discussion about HHS policy should be dismissed as baseless speculation unless officially announced" [3].
The potential withdrawal of COVID-19 vaccines comes amid growing skepticism and controversy surrounding the vaccines. In August, a gunman attacked the CDC headquarters in Atlanta, allegedly targeting the agency because of his COVID-19 vaccine beliefs. A group of former CDC employees blamed Kennedy for vilifying the agency's workforce through "his continuous lies about science and vaccine safety, which have fueled a climate of hostility and mistrust" [2].
References:
[1] https://caliber.az/en/post/trump-administration-may-pull-covid-vaccine-within-months
[2] https://www.inkl.com/news/trump-administration-plans-to-pull-covid-19-vaccines-off-market-within-months
[3] https://www.investing.com/news/stock-market-news/moderna-stock-falls-pfizer-dips-on-covid-vaccine-ban-speculation-93CH-4209558
MRNA--
NVAX--
PFE--
The Trump administration is reportedly preparing to withdraw COVID-19 vaccines from the US market within months, according to a Daily Beast report. The move is based on a recommendation from Dr. Aseem Malhotra, a close associate of HHS Secretary Robert F. Kennedy. However, there is no confirmation of the plan from the administration.
The Trump administration is reportedly preparing to withdraw COVID-19 vaccines from the U.S. market within months, according to a Daily Beast report. The move is based on a recommendation from Dr. Aseem Malhotra, a close associate of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. However, there is no confirmation of the plan from the administration.Dr. Malhotra, a British cardiologist and vocal vaccine critic, told The Daily Beast that members of President Donald Trump's family support Kennedy's position, despite lacking medical or scientific expertise. Malhotra is an adviser to Make America Healthy Again (MAHA) Action, a group aligned with Kennedy's public health agenda [1].
The potential withdrawal of COVID-19 vaccines could have significant implications for the market. Following the report, stocks of vaccine manufacturers, including Pfizer Inc. (NYSE:PFE), BioNTech SE (NASDAQ:BNTX), Moderna Inc. (NASDAQ:MRNA), and Novavax Inc. (NASDAQ:NVAX), began trading lower. Pfizer's stock fell by 2.53%, BioNTech's by 3.31%, Moderna's by 4.48%, and Novavax's by 4.27% [2].
The decision to withdraw the vaccine is reportedly rooted in skepticism about the safety of mRNA vaccines. Central to Kennedy's stance is a 2022 peer-reviewed paper published in the journal Vaccine, which claimed mRNA vaccines were associated with a 16% higher rate of serious adverse events than placebos in clinical trials. However, the study has been widely dismissed by the scientific community due to methodological concerns and claims of bias [1].
The White House has denied these claims. White House spokesperson Kush Desai stated, "The Administration is relying on Gold Standard Science and is committed to radical transparency to make decisions that affect all Americans. Any discussion about HHS policy should be dismissed as baseless speculation unless officially announced" [3].
The potential withdrawal of COVID-19 vaccines comes amid growing skepticism and controversy surrounding the vaccines. In August, a gunman attacked the CDC headquarters in Atlanta, allegedly targeting the agency because of his COVID-19 vaccine beliefs. A group of former CDC employees blamed Kennedy for vilifying the agency's workforce through "his continuous lies about science and vaccine safety, which have fueled a climate of hostility and mistrust" [2].
References:
[1] https://caliber.az/en/post/trump-administration-may-pull-covid-vaccine-within-months
[2] https://www.inkl.com/news/trump-administration-plans-to-pull-covid-19-vaccines-off-market-within-months
[3] https://www.investing.com/news/stock-market-news/moderna-stock-falls-pfizer-dips-on-covid-vaccine-ban-speculation-93CH-4209558

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios